Does the media refer more to PLSE or GMED?

In the previous week, Pulse Biosciences had 1 more articles in the media than Globus Medical. MarketBeat recorded 4 mentions for Pulse Biosciences and 3 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.17 beat Pulse Biosciences' score of 1.05 indicating that Globus Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GKOS or PLSE more profitable?

Glaukos has a net margin of -30.68% compared to Pulse Biosciences' net margin of -6,755.78%. Glaukos' return on equity of -6.37% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% Pulse Biosciences -6,755.78% -94.42% -79.96%

Does the media prefer GKOS or PLSE?

In the previous week, Glaukos had 14 more articles in the media than Pulse Biosciences. MarketBeat recorded 18 mentions for Glaukos and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.05 beat Glaukos' score of 1.02 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, PLSE or PODD?

Insulet has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 9,602.39 -$72.78M -$1.18 N/A Insulet $3.05B 3.26 $247.10M $5.35 26.81

Is PLSE or PODD more profitable?

Insulet has a net margin of 12.29% compared to Pulse Biosciences' net margin of -6,755.78%. Insulet's return on equity of 29.29% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Pulse Biosciences -6,755.78% -94.42% -79.96% Insulet 12.29% 29.29% 13.31%

Does the media favor PLSE or PODD?

In the previous week, Insulet had 49 more articles in the media than Pulse Biosciences. MarketBeat recorded 53 mentions for Insulet and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.05 beat Insulet's score of 0.59 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 19 Very Positive mention(s) 2 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PLSE or TFX?

In the previous week, Teleflex had 8 more articles in the media than Pulse Biosciences. MarketBeat recorded 12 mentions for Teleflex and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.05 beat Teleflex's score of 0.74 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teleflex 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MMED or PLSE?

In the previous week, MiniMed Group had 3 more articles in the media than Pulse Biosciences. MarketBeat recorded 7 mentions for MiniMed Group and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.05 beat MiniMed Group's score of 0.96 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pulse Biosciences (PLSE) Competitors

$48.56 +0.46 (+0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$48.63 +0.07 (+0.14%)

As of 07:44 PM Eastern

Compare

PLSE vs. GMED, GKOS, PODD, TFX, and MMED

Should you buy Pulse Biosciences stock or one of its competitors? Pulse Biosciences's main competitors and comparable companies include Globus Medical (GMED), Glaukos (GKOS), Insulet (PODD), Teleflex (TFX), and MiniMed Group (MMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Pulse Biosciences compare to Globus Medical?

Pulse Biosciences (NASDAQ:PLSE) and Globus Medical (NYSE:GMED) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Pulse Biosciences presently has a consensus target price of $45.25, indicating a potential downside of 6.82%. Globus Medical has a consensus target price of $101.77, indicating a potential upside of 23.25%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts plainly believe Globus Medical is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88

In the previous week, Pulse Biosciences had 1 more articles in the media than Globus Medical. MarketBeat recorded 4 mentions for Pulse Biosciences and 3 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.17 beat Pulse Biosciences' score of 1.05 indicating that Globus Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pulse Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Globus Medical has a net margin of 17.02% compared to Pulse Biosciences' net margin of -6,755.78%. Globus Medical's return on equity of 14.57% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Globus Medical	17.02%	14.57%	12.62%

Globus Medical has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	9,602.39	-$72.78M	-$1.18	N/A
Globus Medical	$2.94B	3.77	$537.87M	$3.91	21.12

Summary

Globus Medical beats Pulse Biosciences on 13 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Glaukos?

Glaukos (NYSE:GKOS) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Glaukos had 14 more articles in the media than Pulse Biosciences. MarketBeat recorded 18 mentions for Glaukos and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.05 beat Glaukos' score of 1.02 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pulse Biosciences has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	21.15	-$187.69M	-$3.25	N/A
Pulse Biosciences	$350K	9,602.39	-$72.78M	-$1.18	N/A

Glaukos has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

99.0% of Glaukos shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Glaukos has a net margin of -30.68% compared to Pulse Biosciences' net margin of -6,755.78%. Glaukos' return on equity of -6.37% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Glaukos currently has a consensus target price of $178.08, suggesting a potential downside of 2.13%. Pulse Biosciences has a consensus target price of $45.25, suggesting a potential downside of 6.82%. Given Glaukos' stronger consensus rating and higher possible upside, research analysts clearly believe Glaukos is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Glaukos beats Pulse Biosciences on 9 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Insulet?

Pulse Biosciences (NASDAQ:PLSE) and Insulet (NASDAQ:PODD) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Pulse Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Insulet has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

In the previous week, Insulet had 49 more articles in the media than Pulse Biosciences. MarketBeat recorded 53 mentions for Insulet and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.05 beat Insulet's score of 0.59 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	19 Very Positive mention(s)	2 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet has a net margin of 12.29% compared to Pulse Biosciences' net margin of -6,755.78%. Insulet's return on equity of 29.29% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Insulet	12.29%	29.29%	13.31%

77.0% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 0.4% of Insulet shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Insulet has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	9,602.39	-$72.78M	-$1.18	N/A
Insulet	$3.05B	3.26	$247.10M	$5.35	26.81

Pulse Biosciences currently has a consensus price target of $45.25, indicating a potential downside of 6.82%. Insulet has a consensus price target of $195.40, indicating a potential upside of 36.25%. Given Insulet's higher possible upside, analysts plainly believe Insulet is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Insulet beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Teleflex?

Pulse Biosciences (NASDAQ:PLSE) and Teleflex (NYSE:TFX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Pulse Biosciences currently has a consensus price target of $45.25, suggesting a potential downside of 6.82%. Teleflex has a consensus price target of $152.90, suggesting a potential upside of 11.08%. Given Teleflex's higher possible upside, analysts clearly believe Teleflex is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Pulse Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Teleflex has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 0.7% of Teleflex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Teleflex had 8 more articles in the media than Pulse Biosciences. MarketBeat recorded 12 mentions for Teleflex and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.05 beat Teleflex's score of 0.74 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teleflex	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Teleflex has a net margin of -39.67% compared to Pulse Biosciences' net margin of -6,755.78%. Teleflex's return on equity of 11.93% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Teleflex	-39.67%	11.93%	5.44%

Pulse Biosciences has higher earnings, but lower revenue than Teleflex. Pulse Biosciences is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	9,602.39	-$72.78M	-$1.18	N/A
Teleflex	$2.25B	2.59	-$905.64M	-$23.29	N/A

Summary

Teleflex beats Pulse Biosciences on 9 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Pulse Biosciences (NASDAQ:PLSE) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Pulse Biosciences has lower revenue, but higher earnings than MiniMed Group. Pulse Biosciences is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.77	-$333M	-$0.68	N/A
Pulse Biosciences	$350K	9,602.39	-$72.78M	-$1.18	N/A

MiniMed Group presently has a consensus price target of $21.62, indicating a potential upside of 10.79%. Pulse Biosciences has a consensus price target of $45.25, indicating a potential downside of 6.82%. Given MiniMed Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe MiniMed Group is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, MiniMed Group had 3 more articles in the media than Pulse Biosciences. MarketBeat recorded 7 mentions for MiniMed Group and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.05 beat MiniMed Group's score of 0.96 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.0% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MiniMed Group has a net margin of 0.00% compared to Pulse Biosciences' net margin of -6,755.78%. MiniMed Group's return on equity of 0.00% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Summary

MiniMed Group beats Pulse Biosciences on 10 of the 15 factors compared between the two stocks.

Get Pulse Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLSE vs. The Competition

Export

Metric	Pulse Biosciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.36B	$5.70B	$7.20B	$12.94B
Dividend Yield	N/A	1.75%	2.54%	11.02%
P/E Ratio	-41.15	25.96	271.31	24.28
Price / Sales	9,602.39	68.72	645.28	92.31
Price / Cash	N/A	33.21	79.89	53.65
Price / Book	33.72	6.20	13.01	6.26
Net Income	-$72.78M	$149.10M	$3.46B	$348.07M
7 Day Performance	1.48%	0.36%	1.95%	1.40%
1 Month Performance	48.09%	7.55%	8.17%	4.59%
1 Year Performance	206.37%	6.20%	26.28%	17.05%

Pulse Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLSE Pulse Biosciences	1.6602 of 5 stars	$48.56 +1.0%	$45.25 -6.8%	+184.4%	$3.36B	$350K	N/A	140
GMED Globus Medical	4.4434 of 5 stars	$86.71 +1.9%	$101.77 +17.4%	+34.4%	$11.53B	$2.94B	22.18	6,000
GKOS Glaukos	1.8636 of 5 stars	$183.54 -1.1%	$177.33 -3.4%	+92.2%	$10.88B	$507.44M	N/A	1,094	Positive News
PODD Insulet	4.7117 of 5 stars	$148.03 +6.0%	$195.40 +32.0%	-56.8%	$9.94B	$2.71B	27.67	5,400	Trending News Gap Up
TFX Teleflex	3.601 of 5 stars	$132.26 -0.6%	$151.80 +14.8%	+9.0%	$5.81B	$1.99B	N/A	15,500	Positive News Analyst Forecast Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLSE) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulse Biosciences (PLSE) Competitors

PLSE vs. GMED, GKOS, PODD, TFX, and MMED

How does Pulse Biosciences compare to Globus Medical?

Summary

How does Pulse Biosciences compare to Glaukos?

Summary

How does Pulse Biosciences compare to Insulet?

Summary

How does Pulse Biosciences compare to Teleflex?

Summary

How does Pulse Biosciences compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulse Biosciences (PLSE) Competitors

PLSE vs. GMED, GKOS, PODD, TFX, and MMED

How does Pulse Biosciences compare to Globus Medical?

Do analysts recommend PLSE or GMED?

Does the media refer more to PLSE or GMED?

Do institutionals & insiders have more ownership in PLSE or GMED?

Which has more risk & volatility, PLSE or GMED?

Is PLSE or GMED more profitable?

Which has higher valuation & earnings, PLSE or GMED?

Summary

How does Pulse Biosciences compare to Glaukos?

Does the media prefer GKOS or PLSE?

Which has higher valuation & earnings, GKOS or PLSE?

Which has more volatility & risk, GKOS or PLSE?

Do insiders and institutionals hold more shares of GKOS or PLSE?

Is GKOS or PLSE more profitable?

Do analysts recommend GKOS or PLSE?

Summary

How does Pulse Biosciences compare to Insulet?

Which has more risk and volatility, PLSE or PODD?

Does the media favor PLSE or PODD?

Is PLSE or PODD more profitable?

Do insiders & institutionals believe in PLSE or PODD?

Which has higher earnings & valuation, PLSE or PODD?

Do analysts prefer PLSE or PODD?

Summary

How does Pulse Biosciences compare to Teleflex?

Do analysts prefer PLSE or TFX?

Which has more volatility & risk, PLSE or TFX?

Do institutionals & insiders have more ownership in PLSE or TFX?

Does the media favor PLSE or TFX?

Is PLSE or TFX more profitable?

Which has higher valuation & earnings, PLSE or TFX?

Summary

How does Pulse Biosciences compare to MiniMed Group?

Which has better valuation and earnings, MMED or PLSE?

Do analysts recommend MMED or PLSE?

Does the media prefer MMED or PLSE?

Do insiders & institutionals hold more shares of MMED or PLSE?

Is MMED or PLSE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools